DE69927598T2 - Verfahren zur Affinitätstrennung und Liganden zur pertinenten Verwendung - Google Patents
Verfahren zur Affinitätstrennung und Liganden zur pertinenten Verwendung Download PDFInfo
- Publication number
- DE69927598T2 DE69927598T2 DE69927598T DE69927598T DE69927598T2 DE 69927598 T2 DE69927598 T2 DE 69927598T2 DE 69927598 T DE69927598 T DE 69927598T DE 69927598 T DE69927598 T DE 69927598T DE 69927598 T2 DE69927598 T2 DE 69927598T2
- Authority
- DE
- Germany
- Prior art keywords
- protein
- affinity
- derivative
- ligand
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003446 ligand Substances 0.000 title claims abstract description 54
- 238000000034 method Methods 0.000 title claims abstract description 42
- 238000000926 separation method Methods 0.000 title claims abstract description 26
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 121
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 112
- 235000018102 proteins Nutrition 0.000 claims abstract description 107
- 238000009739 binding Methods 0.000 claims abstract description 48
- 230000027455 binding Effects 0.000 claims abstract description 47
- 238000012986 modification Methods 0.000 claims abstract description 8
- 230000004048 modification Effects 0.000 claims abstract description 7
- 235000001014 amino acid Nutrition 0.000 claims description 35
- 229940024606 amino acid Drugs 0.000 claims description 34
- 150000001413 amino acids Chemical class 0.000 claims description 34
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 30
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 30
- 239000012634 fragment Substances 0.000 claims description 27
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 25
- 238000006467 substitution reaction Methods 0.000 claims description 15
- 239000003513 alkali Substances 0.000 claims description 14
- 102000037865 fusion proteins Human genes 0.000 claims description 10
- 108020001507 fusion proteins Proteins 0.000 claims description 10
- 102000009027 Albumins Human genes 0.000 claims description 7
- 108010088751 Albumins Proteins 0.000 claims description 7
- 108010088160 Staphylococcal Protein A Proteins 0.000 claims description 7
- 108091008324 binding proteins Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 102000052510 DNA-Binding Proteins Human genes 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 5
- 101710096438 DNA-binding protein Proteins 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 108020001580 protein domains Proteins 0.000 claims description 2
- 102000023732 binding proteins Human genes 0.000 claims 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract description 14
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract description 7
- 235000009582 asparagine Nutrition 0.000 abstract description 6
- 229960001230 asparagine Drugs 0.000 abstract description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 51
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 241000588724 Escherichia coli Species 0.000 description 12
- 239000012491 analyte Substances 0.000 description 12
- 238000002703 mutagenesis Methods 0.000 description 12
- 231100000350 mutagenesis Toxicity 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 238000004140 cleaning Methods 0.000 description 11
- 238000001042 affinity chromatography Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 230000009870 specific binding Effects 0.000 description 8
- 235000004279 alanine Nutrition 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 229920002684 Sepharose Polymers 0.000 description 6
- 230000006240 deamidation Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010058683 Immobilized Proteins Proteins 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- -1 cyclic imide Chemical class 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000002708 random mutagenesis Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
- 241000724791 Filamentous phage Species 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000001974 tryptic soy broth Substances 0.000 description 2
- 108010050327 trypticase-soy broth Proteins 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- PLVPPLCLBIEYEA-WAYWQWQTSA-N (z)-3-(1h-indol-3-yl)prop-2-enoic acid Chemical compound C1=CC=C2C(\C=C/C(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-WAYWQWQTSA-N 0.000 description 1
- CXCHEKCRJQRVNG-UHFFFAOYSA-N 2,2,2-trifluoroethanesulfonyl chloride Chemical compound FC(F)(F)CS(Cl)(=O)=O CXCHEKCRJQRVNG-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- KLKHFFMNGWULBN-VKHMYHEASA-N Asn-Gly Chemical compound NC(=O)C[C@H](N)C(=O)NCC(O)=O KLKHFFMNGWULBN-VKHMYHEASA-N 0.000 description 1
- SONUFGRSSMFHFN-IMJSIDKUSA-N Asn-Ser Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O SONUFGRSSMFHFN-IMJSIDKUSA-N 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 241000194015 Streptococcus sp. G148 Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 229940093740 amino acid and derivative Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 125000003164 beta-aspartyl group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PLVPPLCLBIEYEA-UHFFFAOYSA-N indoleacrylic acid Natural products C1=CC=C2C(C=CC(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-UHFFFAOYSA-N 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9823071 | 1998-10-21 | ||
| GBGB9823071.7A GB9823071D0 (en) | 1998-10-21 | 1998-10-21 | A method |
| PCT/GB1999/003484 WO2000023580A1 (en) | 1998-10-21 | 1999-10-21 | A method of affinity separation and ligands for use therein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69927598D1 DE69927598D1 (de) | 2006-02-16 |
| DE69927598T2 true DE69927598T2 (de) | 2006-07-13 |
Family
ID=10841043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69927598T Expired - Lifetime DE69927598T2 (de) | 1998-10-21 | 1999-10-21 | Verfahren zur Affinitätstrennung und Liganden zur pertinenten Verwendung |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6831161B1 (enExample) |
| EP (2) | EP1672068A1 (enExample) |
| JP (1) | JP4801258B2 (enExample) |
| AT (1) | ATE305970T1 (enExample) |
| AU (1) | AU773368B2 (enExample) |
| CA (2) | CA2347960C (enExample) |
| DE (1) | DE69927598T2 (enExample) |
| DK (1) | DK1123389T3 (enExample) |
| GB (1) | GB9823071D0 (enExample) |
| NO (1) | NO323994B1 (enExample) |
| WO (1) | WO2000023580A1 (enExample) |
| ZA (1) | ZA200103252B (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0200943D0 (sv) | 2002-03-25 | 2002-03-25 | Amersham Biosciences Ab | Mutant protein |
| US7709209B2 (en) | 2002-03-25 | 2010-05-04 | Ge Healthcare Bio-Sciences Ab | Protein ligands |
| GB0214007D0 (en) * | 2002-06-18 | 2002-07-31 | Common Services Agency | Removal of prion infectivity |
| EP1634076A2 (en) * | 2003-06-10 | 2006-03-15 | CatchMabs B.V. | Binding peptides: methods for their generation and use |
| SE0301936D0 (sv) * | 2003-06-30 | 2003-06-30 | Affibody Ab | New polypeptide |
| WO2005003156A1 (en) * | 2003-07-04 | 2005-01-13 | Affibody Ab | Polypeptides having binding affinity for her2 |
| WO2005097202A2 (en) | 2004-04-06 | 2005-10-20 | Affibody Ab | Use of serum albumin binding peptides conjugates for the preparation of a medicament |
| AU2007300751B2 (en) | 2006-09-29 | 2012-01-19 | Cytiva Bioprocess R&D Ab | Chromatography ligand comprising Domain C from Staphyloccocus aureus protein A for antibody isolation |
| EP2190863B1 (en) * | 2007-07-31 | 2015-09-02 | Affibody AB | New albumin binding compositions, methods and uses |
| GB2452301A (en) * | 2007-08-30 | 2009-03-04 | Ge Healthcare Bio Sciences Ab | Sterilization Method |
| US8592555B2 (en) | 2008-08-11 | 2013-11-26 | Emd Millipore Corporation | Immunoglobulin-binding proteins with improved specificity |
| WO2010035757A1 (ja) * | 2008-09-25 | 2010-04-01 | Jsr株式会社 | アフィニティークロマトグラフィー用充填剤 |
| JP5229888B2 (ja) * | 2008-09-30 | 2013-07-03 | 独立行政法人産業技術総合研究所 | 弱酸性域での易解離性を向上したプロテインａ変異型タンパク質及び抗体捕捉剤 |
| SG195555A1 (en) | 2008-12-24 | 2013-12-30 | Emd Millipore Corp | Caustic stable chromatography ligands |
| EP2412809B1 (en) | 2009-03-24 | 2017-08-09 | Kaneka Corporation | Protein having affinity for immunoglobulin, and immunoglobulin-binding affinity ligand |
| WO2011118699A1 (ja) | 2010-03-24 | 2011-09-29 | 株式会社カネカ | 免疫グロブリンに特異的に結合するタンパク質および免疫グロブリン結合性アフィニティーリガンド |
| JP5997176B2 (ja) * | 2010-12-21 | 2016-09-28 | ザ ユニバーシティ オブ ウエスタン オンタリオＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｗｅｓｔｅｒｎ Ｏｎｔａｒｉｏ | プロテインａの新規アルカリ抵抗性変異体及びアフィニティークロマトグラフィーにおけるその使用 |
| CN103270044B (zh) | 2010-12-21 | 2016-03-09 | Jsr株式会社 | 亲和色谱用载体和分离免疫球蛋白的方法 |
| JP6038774B2 (ja) | 2011-03-24 | 2016-12-07 | 株式会社カネカ | タンパク性物質結合性低分子化合物 |
| SG193950A1 (en) | 2011-03-25 | 2013-11-29 | Kaneka Corp | Novel immunoglobulin-binding polypeptide |
| SG186552A1 (en) | 2011-06-08 | 2013-01-30 | Emd Millipore Corp | Chromatography matrices including novel staphylococcus aureus protein a based ligands |
| WO2014076179A1 (en) | 2012-11-14 | 2014-05-22 | Affibody Ab | New polypeptide |
| WO2014076177A1 (en) * | 2012-11-14 | 2014-05-22 | Affibody Ab | New polypeptide |
| US9255262B2 (en) * | 2013-03-06 | 2016-02-09 | Vision Global Holdings Ltd. | Albumin-binding arginine deminase and the use thereof |
| USRE48805E1 (en) | 2013-03-06 | 2021-11-02 | Vision Global Holdings Ltd. | Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein |
| US11014129B2 (en) | 2013-09-04 | 2021-05-25 | Emd Millipore Corporation | Methods of cleaning a protein A based affinity chromatography column |
| JP6491600B2 (ja) | 2013-09-27 | 2019-03-27 | 株式会社カネカ | アルカリ水溶液を用いた多孔質セルロースビーズの製造方法 |
| WO2015088677A1 (en) | 2013-12-12 | 2015-06-18 | Emd Millipore Corporation | Protein separations using an acrylamide containing filter |
| JP6369807B2 (ja) * | 2014-10-21 | 2018-08-08 | 株式会社プロテイン・エクスプレス | プロテインｌ変異体 |
| JP6663360B2 (ja) | 2015-01-26 | 2020-03-11 | 株式会社カネカ | 変異型免疫グロブリンκ鎖可変領域結合性ペプチド |
| WO2016121701A1 (ja) | 2015-01-26 | 2016-08-04 | 株式会社カネカ | 免疫グロブリンκ鎖可変領域含有タンパク質精製用アフィニティー分離マトリックス |
| EP3276002B1 (en) | 2015-03-26 | 2020-04-29 | JSR Corporation | Immunoglobulin-binding protein and affinity carrier using same |
| EP3875477A1 (en) | 2015-04-17 | 2021-09-08 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| EP3375873B1 (en) | 2015-10-22 | 2025-07-02 | Protenova Co., Ltd. | Immunoglobulin-binding polypeptide |
| WO2017191748A1 (ja) * | 2016-05-02 | 2017-11-09 | 株式会社カネカ | 改変型免疫グロブリンκ鎖可変領域結合性ペプチド |
| WO2017195638A1 (ja) | 2016-05-09 | 2017-11-16 | 株式会社カネカ | 抗体またはκ鎖可変領域含有抗体断片の精製方法 |
| EP3592759A1 (en) | 2017-03-07 | 2020-01-15 | JMVA Biotech AB | Modified adsorptive surfaces |
| US11753449B2 (en) | 2017-09-25 | 2023-09-12 | Jsr Corporation | Immunoglobulin binding protein, and affinity support using same |
| JP7724061B2 (ja) | 2018-04-11 | 2025-08-15 | インヒブルクス バイオサイエンシズ インコーポレイテッド | 制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物ならびに関連する方法および使用 |
| US12428451B2 (en) | 2018-08-24 | 2025-09-30 | Jsr Corporation | Immunoglobulin-binding protein, and affinity carrier using same |
| JP2023551353A (ja) | 2020-10-13 | 2023-12-08 | アヴィタイド エルエルシー | ３へリックスバンドルタンパク質の親和性リガンドライブラリー及びその使用 |
| CN116670150A (zh) | 2020-12-22 | 2023-08-29 | 普罗泰纳瓦株式会社 | 免疫球蛋白结合多肽 |
| WO2022178396A1 (en) | 2021-02-19 | 2022-08-25 | Avitide LLC | Aav2 affinity agents |
| GB2609185A (en) | 2021-05-24 | 2023-02-01 | Astrea Uk Services Ltd | Scaffold for isolation of a biomolecule |
| EP4541814A1 (en) * | 2023-10-20 | 2025-04-23 | Cytiva BioProcess R&D AB | Stabilized polypeptides |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE462046C (sv) * | 1982-08-23 | 1998-04-27 | Pharmacia Biotech Ab | Hybrid-DNA-vektor innehållande DNA-sekvens från Staphylococcus aureus, förfarande för dess framställning och bakterie innehållande densamma |
| US5401832A (en) * | 1984-12-24 | 1995-03-28 | Merck & Co., Inc. | Brain derived and recombinant acidic fibroblast growth factor |
| US5089473A (en) * | 1988-08-29 | 1992-02-18 | Monsanto Company | Somatotropin variants and their use |
| EP0863210A3 (en) * | 1991-07-25 | 1999-09-22 | Oriental Yeast Co., Ltd. | Immunoglobulin-binding artificial protein |
| JP2584697B2 (ja) * | 1991-08-23 | 1997-02-26 | オリエンタル酵母工業株式会社 | ＩｇＧ精製用組換え型プロテインＡ |
| DE59306762D1 (de) * | 1992-04-16 | 1997-07-24 | Merck Patent Gmbh | Aktivierte Trägermaterialien, ihre Herstellung und Verwendung |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| US5736499A (en) * | 1995-06-06 | 1998-04-07 | Genencor International, Inc. | Mutant A-amylase |
| SE9503925D0 (sv) * | 1995-11-07 | 1995-11-07 | Pharmacia Biotech Ab | Separationsmedium för IgG |
| EP0968290B1 (en) * | 1997-03-12 | 2004-12-15 | SmithKline Beecham Corporation | Anti-alphavbeta3 humanized monoclonal antibodies |
-
1998
- 1998-10-21 GB GBGB9823071.7A patent/GB9823071D0/en not_active Ceased
-
1999
- 1999-10-21 AT AT99950942T patent/ATE305970T1/de not_active IP Right Cessation
- 1999-10-21 AU AU63532/99A patent/AU773368B2/en not_active Expired
- 1999-10-21 JP JP2000577291A patent/JP4801258B2/ja not_active Expired - Lifetime
- 1999-10-21 US US09/830,080 patent/US6831161B1/en not_active Expired - Lifetime
- 1999-10-21 EP EP05077192A patent/EP1672068A1/en not_active Ceased
- 1999-10-21 WO PCT/GB1999/003484 patent/WO2000023580A1/en not_active Ceased
- 1999-10-21 CA CA002347960A patent/CA2347960C/en not_active Expired - Lifetime
- 1999-10-21 DK DK99950942T patent/DK1123389T3/da active
- 1999-10-21 DE DE69927598T patent/DE69927598T2/de not_active Expired - Lifetime
- 1999-10-21 EP EP99950942A patent/EP1123389B1/en not_active Expired - Lifetime
- 1999-10-21 CA CA2633345A patent/CA2633345C/en not_active Expired - Lifetime
-
2001
- 2001-04-20 NO NO20011969A patent/NO323994B1/no not_active IP Right Cessation
- 2001-04-20 ZA ZA200103252A patent/ZA200103252B/en unknown
-
2004
- 2004-12-01 US US11/000,747 patent/US20050100970A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200103252B (en) | 2002-07-22 |
| NO20011969D0 (no) | 2001-04-20 |
| CA2633345A1 (en) | 2000-04-27 |
| JP2002527107A (ja) | 2002-08-27 |
| DK1123389T3 (da) | 2006-01-16 |
| CA2347960A1 (en) | 2000-04-27 |
| CA2347960C (en) | 2008-08-05 |
| CA2633345C (en) | 2013-02-26 |
| AU6353299A (en) | 2000-05-08 |
| EP1123389A1 (en) | 2001-08-16 |
| GB9823071D0 (en) | 1998-12-16 |
| AU773368B2 (en) | 2004-05-20 |
| ATE305970T1 (de) | 2005-10-15 |
| DE69927598D1 (de) | 2006-02-16 |
| NO323994B1 (no) | 2007-07-30 |
| US20050100970A1 (en) | 2005-05-12 |
| NO20011969L (no) | 2001-06-19 |
| EP1672068A1 (en) | 2006-06-21 |
| WO2000023580A1 (en) | 2000-04-27 |
| US6831161B1 (en) | 2004-12-14 |
| EP1123389B1 (en) | 2005-10-05 |
| JP4801258B2 (ja) | 2011-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69927598T2 (de) | Verfahren zur Affinitätstrennung und Liganden zur pertinenten Verwendung | |
| DE69533644T2 (de) | Rezeptorstrukturen aus bakterien | |
| DE69731084T2 (de) | REINIGUNG DES GEWEBE PLASMINOGENAKTIVATORS (tPA) | |
| DE60124678T2 (de) | Proteingerüste für antikörper-mimetika und andere bindungsproteine | |
| DE69032483T2 (de) | Zellfreie synthese und isolierung von genen und polypeptiden | |
| DE69129154T2 (de) | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften | |
| DE3852304T3 (de) | Organismus als Träger für "Single Chain Antibody Domain (SCAD)". | |
| AT503861A1 (de) | Verfahren zur manipulation von t-zell-rezeptoren | |
| DE10113776A1 (de) | Sequenziell angeordnete streptavidinbindende Module als Affinitätsanhängsel | |
| DE3750379T3 (de) | Varianten des abbaubeschleunigenden Faktors (DAF), hergestellt durch rekombinante DNS-Technologie. | |
| DE60123819T2 (de) | Methode zur in vivo identifizierung von intrazellularen epitopen | |
| DE69318495T2 (de) | Verfahren zur Reinigung des Big-Endothelin Proteins | |
| US7439334B2 (en) | Method of arrangement of titanium-binding ferritin and inorganic particles | |
| DE4344350C2 (de) | Bakterien zur Herstellung stabiler Fusionsproteine und Verfahren zu deren Nachweis | |
| WO2009018964A2 (de) | System, umfassend wirkstoffe umfassende partikel und bakteriophagen | |
| EP1245238B1 (de) | Exotoxin-Ligand | |
| DE69031925T2 (de) | Multifunktionale Polypeptide und Verfahren zu deren Herstellung | |
| WO2002092612A2 (de) | Enterotoxin b bindende nukleinsäure | |
| DE69333106T2 (de) | Polypeptidproduktion | |
| DE102005011579B4 (de) | Affinitätsmarker zur Proteinreinigung, seine Herstellung und Verwendung sowie Verfahren zur Aufreinigung eines Proteins | |
| DE102004010928A1 (de) | Protein zur Bindung prokaryonter DNA sowie Verfahren zur Trennung und Anreicherung prokaryonter DNA | |
| DE3931841A1 (de) | Dopamin-d2-rezeptor | |
| DE19964015A1 (de) | Verfahren zur Entfernung oder Abtrennung von Viren in potentiell Viren enthaltenden Proben | |
| WO2010060507A1 (de) | Verfahren zur hochdurchsatzfähigen präparation sequenzierungsfähiger dna aus enzelnen plaques von peptiden präsentierenden phagen | |
| EP1144606A2 (de) | Menschliche angiogeneserelevante nukleinsäure- und protein-sequenzen aus endothelzellen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: AFFIBODY AB, BROMMA, SE |